Increasing demand for non-invasive biomarkers to catapult growth in the exosome diagnostic and therapeutic market. The market size is expected to increase from USD 88.56 million in 2024 to USD 211.6 million by 2034, at a 9.10% CAGR.
| Attributes | Key Insights |
|---|---|
| Estimated Exosomes Diagnostic and Therapeutic Market Size (2024E) | USD 88.56 million |
| Projected Exosomes Diagnostic and Therapeutic Market Valuation (2034F) | USD 211.6 million |
| Value-based CAGR (2024 to 2034) | 9.10% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The healthcare sector is facing pressure to reduce the prices of healthcare services to increase their accessibility among the rising patient population. In this regard, laboratories are adopting solutions that are integrated with informatics. This helps boost productivity with the help of available resources.
Manufacturers are taking an opportunistic approach by offering such healthcare facilities with additional services and support in terms of diagnostic test products. Consequently, contributes to market growth.
Key players are also capitalizing on the growing demand for non-invasive tests to diagnose cancer. For this, they continue to maintain partnerships with academic institutes to develop novel non-invasive diagnostics.
| Leading Application | Diagnostics |
|---|---|
| Value Share (2024) | 68.0% |
Based on application, the exosome-based diagnostics segment acquired a massive value share of 68% in 2023. Significant use of exosomes for diagnostic purposes can be attributed to their effective delivery of specific disease cells like nucleic acids and proteins. Exosome diagnostic tests are presently being developed for several diseases like infectious diseases, cancer, and neurological disorders.
| Leading Product Type | Instruments |
|---|---|
| Value Share (2024) | 25.0% |
By product type, the instruments segment accounts for a prominent share of 25% in the exosomes diagnostic and therapeutic market. The segment is driven by rapid advancements in research and development activities in the healthcare sector. Growth in the count of manufacturers providing instruments for diagnostic and therapeutic is also propelling the segment expansion.
| Countries | Forecast CAGR (2024 to 2034) |
|---|---|
| The United States | 4.50% |
| Canada | 5.0% |
| Germany | 3.80% |
| China | 10.0% |
| India | 9.50% |
Market players are exploiting the potential for the exosome diagnostic and therapeutic industry in the United States, which is estimated to grow at 4.5% CAGR over the forecast period. Exosomes have been receiving significant traction over the past few years due to their remarkable therapeutic possibilities.
They can be harnessed for focused delivery of therapeutic agents, like nucleic acids, proteins, and pharmaceuticals, nucleic acids, throughout biological barriers. This attribute holds a lot of potential in precision medicine applications, especially in cancer therapy.
Numerous cutting-edge technologies and the latest strategies have been developed to harness the capability of exosomes to enhance the efficiency and precision of cancer detection. These approaches can revolutionize cancer diagnostics, offering non-invasive, more precise, and early detection methods.
Liquid biopsies are one such disruptive strategy in cancer treatment, which uses non-invasive collection and investigation of exosomes from body fluids like urine, blood, and saliva.
The rapid increase in cancer patients and surging funding for cancer-related research are expected to continue supporting the exosome diagnostic and therapeutic industry in the United States.
Adoption of exosomes diagnostic and therapeutic in Canada is projected to surge at a CAGR of 5% through 2034. Growth of this industry is increasing as researchers are trying to understand the connection between kidney function and disorders and urinary exosomes since exosomes carry cargo across kidney cells.
The availability, non-invasive nature, and ease of sample collection of urinary exosomes make them remarkable. Non-invasive exosomes offer a cost-effective way to uncover disease causes and therapeutic targets owing to their prognostic and diagnostic sensitivity. Additionally, non-invasive biomarkers have more patient and clinical adoption than their invasive counterparts.
Conveniently distributable and cost-effective distributable urinary indicators are clinically accessible. These factors contribute to the growth of the exosomes diagnostic and therapeutic market.
The scope of exosomes diagnostic and therapeutic in Germany is estimated to expand at a CAGR of 3.80% over the next 10 years. The industry is expected to be propelled by the increasing count of research activities with a focus on applications of exosomes to access the therapeutic effects of stem cells within the country.
Growing demand for advanced diagnostic assays as well as the increasing incidence of cancer in Germany are contributing to exosomes diagnostic and therapeutic market growth. Certain common factors that are compelling growth in the industry include advancements in healthcare systems and surging funding for research and development in Germany.
Investments in the Indian market are projected to rise at a CAGR of 9.5% in the following decade. Increasing cases of diseases like infectious disorders, cancer, and neurological diseases in India are raising the demand for more effective treatment and diagnostic tools offered by exosomes.
Ongoing technological advancements like proteomic analysis and high-throughput techniques are facilitating the characterization and identification of exosomes. Along with this, technological progress is helping in the development of diagnostic therapies and tools based on exosomes.
Surging investments from government agencies, private investors, and pharmaceutical firms are promoting research and growth in exosome diagnostics and therapeutics. With improving regulatory acceptance for exosome-based products, the market is set for significant expansion.
Demand for exosome diagnostic and therapeutic in China is expected to rise at a CAGR of 10% over the forecast period. The market is driven by an increase in clinically researched and perceived applications of exosomes as smart nano-platforms for therapy and diagnosis in the country. Additionally, market players in China are increasing their efforts to exhibit the utility of exosomes in non-invasive testing to accelerate its adoption.
The exosome diagnostic and therapeutic industry is experiencing a high level of competition, thanks to the growing count of companies manufacturing exosome-based products. All known companies in the market are covered below. Along with the companies, the technology that they are working on is also described. The following companies may or may not be working with any regulatory agencies, however, many of them do.
AcouSort AB
It is a Swedish firm that is introducing a revolutionary acoustofluidic technology and working on exosome-based diagnostics. The European Innovation Council (EIC) rewarded AcouSort and its project partners with a total of USD 2.5 million to create acoustofluidic thin-film actuated chip to separate exosomes from blood.
Aethlon Medical, Inc.
It is a United States-based company that focuses on addressing the unmet requirements in the global health and biodefense industry. The firm began its tumor-derived exosome research when the medical community held a view that exosomes are cellular debris.
Fast-forward to the present, a therapeutic to attend to tumor-derived exosomes presents a significant gap in cancer care. Aethlon has shown that Hemopurifier®’s affinity mechanism can detect tumor-derived exosomes behind various forms of cancer, like ovarian, breast, and metastatic melanoma.
AGC Biologics
AGC Biologics came into a service agreement with Japan’s Jikei University in April 2023. This agreement states that AGC Biologics is going to assume a feasibility study and technology transfer for a drug to cure idiopathic pulmonary fibrosis (IPF). Specifically, the ACG scientists are going to focus on recognizing the viability of developing a sample for an exosome-based treatment.
Aruna Bio
The company is leveraging the natural abilities of neural exosomes to pass the blood-brain barrier and elevate the body’s anti-inflammatory, protective, and self-repair mechanisms for neurodegenerative disorders treatment.
Latest Developments in the Exosomes Diagnostic and Therapeutic Market
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
For the year 2024, the exosomes diagnostic and therapeutic industry is estimated to be valued at USD 88.56 million.
The adoption rate of exosomes diagnostic and therapeutic is calculated to be around 9.10% for the forecast period.
The market revenue is expected to shoot up to USD 211.6 million by 2034.
The diagnostics segment grabs a hefty share within the exosomes diagnostic and therapeutic industry.
China is expected to register a significant growth rate in the exosomes diagnostic and therapeutic industry.
Anjarium Biosciences AG, Aruna Bio, and Brexogen are influential players in the exosome diagnostic and therapeutic industry.
| Market Size (2024) | USD 394.3 million |
|---|---|
| Market Value (2034) | USD 5,100 million |
| Market Projected CAGR (2024 to 2034) | 29.1% |
| Market Size (2023) | USD 196.8 million |
|---|---|
| Market Size (2033) | USD 888.5 million |
| CAGR (2023 to 2033) | 16.3% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Exosomes Diagnostic and Therapeutic Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
